D(2) dopamine receptor

Timeframe	Studies on this Protein(%)	All Drugs %
pre-1990	6 (1.36)	18.7374
1990's	70 (15.84)	18.2507
2000's	156 (35.29)	29.6817
2010's	166 (37.56)	24.3611
2020's	44 (9.95)	2.80

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
7-hydroxy-2-n,n-dipropylaminotetralin	Homo sapiens (human)	Ki	0.1263	5	5
8-hydroxy-2-(di-n-propylamino)tetralin	Homo sapiens (human)	IC50	1.0000	1	1
8-hydroxy-2-(di-n-propylamino)tetralin	Homo sapiens (human)	Ki	0.7002	5	5
octoclothepine	Homo sapiens (human)	Ki	0.0007	1	1
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin	Homo sapiens (human)	Ki	0.0098	2	2
sk&f-38393	Homo sapiens (human)	Ki	720.0000	1	1
1-(1-naphthyl)piperazine	Homo sapiens (human)	IC50	1.0000	1	1
1-(2-methoxyphenyl)piperazine	Homo sapiens (human)	IC50	1.0000	1	1
1-(2-methoxyphenyl)piperazine	Homo sapiens (human)	Ki	2.9545	2	3
1-(3-chlorophenyl)piperazine	Homo sapiens (human)	Ki	10.0000	1	1
3-[(4-chlorophenyl)-phenylmethoxy]-8-methyl-8-azabicyclo[3.2.1]octane	Homo sapiens (human)	Ki	1.7400	1	1
5-carboxamidotryptamine	Homo sapiens (human)	Ki	0.0005	1	1
amiodarone	Homo sapiens (human)	IC50	19.9520	1	0
amiodarone	Homo sapiens (human)	Ki	6.6510	1	0
dan 2163	Homo sapiens (human)	IC50	0.0030	1	1
dan 2163	Homo sapiens (human)	Ki	0.0078	2	2
amitriptyline	Homo sapiens (human)	IC50	1.0090	1	0
amitriptyline	Homo sapiens (human)	Ki	0.2660	2	1
amoxapine	Homo sapiens (human)	IC50	0.2000	1	0
amoxapine	Homo sapiens (human)	Ki	0.0670	1	0
astemizole	Homo sapiens (human)	IC50	4.5210	1	0
astemizole	Homo sapiens (human)	Ki	1.5070	1	0
bmy 7378	Homo sapiens (human)	Ki	0.0140	1	1
buspirone	Homo sapiens (human)	IC50	0.3230	1	0
buspirone	Homo sapiens (human)	Ki	0.3131	7	6
carvedilol	Homo sapiens (human)	IC50	0.1460	1	0
carvedilol	Homo sapiens (human)	Ki	0.0490	1	0
chlorpromazine	Homo sapiens (human)	IC50	0.0142	5	4
chlorpromazine	Homo sapiens (human)	Ki	0.0059	9	8
cisapride	Homo sapiens (human)	IC50	0.3500	2	1
cisapride	Homo sapiens (human)	Ki	0.1580	1	0
clebopride	Homo sapiens (human)	Ki	0.0150	2	2
clomipramine	Homo sapiens (human)	IC50	0.4130	1	0
clomipramine	Homo sapiens (human)	Ki	0.1380	1	0
clotrimazole	Homo sapiens (human)	IC50	12.1860	1	0
clotrimazole	Homo sapiens (human)	Ki	4.0620	1	0
cyproheptadine	Homo sapiens (human)	IC50	0.1640	1	0
cyproheptadine	Homo sapiens (human)	Ki	0.0835	2	1
diphenidol	Homo sapiens (human)	IC50	3.2900	1	0
diphenidol	Homo sapiens (human)	Ki	1.0970	1	0
disulfiram	Homo sapiens (human)	IC50	23.0180	1	0
disulfiram	Homo sapiens (human)	Ki	7.6730	1	0
domperidone	Homo sapiens (human)	IC50	0.0026	1	0
domperidone	Homo sapiens (human)	Ki	0.0009	1	0
adtn	Homo sapiens (human)	IC50	0.0000	1	1
droperidol	Homo sapiens (human)	IC50	0.0024	1	0
droperidol	Homo sapiens (human)	Ki	0.0008	1	0
ebastine	Homo sapiens (human)	IC50	0.6050	2	1
ebastine	Homo sapiens (human)	Ki	0.3830	1	0
econazole	Homo sapiens (human)	IC50	12.8070	1	0
econazole	Homo sapiens (human)	Ki	4.2690	1	0
fenoldopam	Homo sapiens (human)	Ki	0.8100	1	1
fentanyl	Homo sapiens (human)	Ki	21.0000	1	1
fluphenazine	Homo sapiens (human)	IC50	0.0016	1	0
fluphenazine	Homo sapiens (human)	Ki	0.0010	2	1
formoterol fumarate	Homo sapiens (human)	IC50	10.0000	1	1
formoterol fumarate	Homo sapiens (human)	Ki	13.0000	1	1
haloperidol	Homo sapiens (human)	IC50	0.0897	10	10
haloperidol	Homo sapiens (human)	Ki	0.0693	96	98
hydroxyzine	Homo sapiens (human)	Ki	0.3780	1	1
ifenprodil	Homo sapiens (human)	IC50	1.0000	1	1
imipramine	Homo sapiens (human)	IC50	0.4100	1	1
imipramine	Homo sapiens (human)	Ki	0.7260	1	1
isoproterenol	Homo sapiens (human)	Ki	30.0000	2	2
jl 18	Homo sapiens (human)	Ki	5.9400	1	1
ketanserin	Homo sapiens (human)	Ki	0.1218	2	2
loperamide	Homo sapiens (human)	Ki	5.7900	1	1
loxapine	Homo sapiens (human)	IC50	0.0540	1	1
loxapine	Homo sapiens (human)	Ki	0.0210	2	2
maprotiline	Homo sapiens (human)	IC50	3.4630	1	0
maprotiline	Homo sapiens (human)	Ki	0.9095	2	1
methadone	Homo sapiens (human)	Ki	100.0000	1	1
metoclopramide	Homo sapiens (human)	IC50	0.1270	1	0
metoclopramide	Homo sapiens (human)	Ki	0.0420	1	0
mianserin	Homo sapiens (human)	IC50	7.0795	2	2
mianserin	Homo sapiens (human)	Ki	2.1970	1	1
miconazole	Homo sapiens (human)	IC50	12.5040	1	0
miconazole	Homo sapiens (human)	Ki	4.1680	1	0
mirtazapine	Homo sapiens (human)	Ki	5.4540	1	1
modafinil	Homo sapiens (human)	Ki	100.0000	1	1
moperone	Homo sapiens (human)	Ki	0.0007	1	1
nemonapride	Homo sapiens (human)	Ki	0.0026	1	1
ondansetron	Homo sapiens (human)	Ki	10.0000	1	1
perphenazine	Homo sapiens (human)	IC50	0.0003	1	1
procaterol	Homo sapiens (human)	Ki	86.0000	1	1
prochlorperazine	Homo sapiens (human)	IC50	0.0110	1	0
prochlorperazine	Homo sapiens (human)	Ki	0.0036	1	0
promazine	Homo sapiens (human)	IC50	0.5050	1	0
promazine	Homo sapiens (human)	Ki	0.1680	1	0
promethazine	Homo sapiens (human)	IC50	0.4395	2	1
promethazine	Homo sapiens (human)	Ki	0.2600	1	0
propranolol	Homo sapiens (human)	IC50	5.0119	1	1
quetiapine	Homo sapiens (human)	IC50	1.3299	1	0
quetiapine	Homo sapiens (human)	Ki	0.2163	7	6
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol	Homo sapiens (human)	Ki	0.0017	1	1
raloxifene	Homo sapiens (human)	IC50	1.1740	1	0
raloxifene	Homo sapiens (human)	Ki	0.3910	1	0
rbi 257	Homo sapiens (human)	Ki	1.0000	1	1
risperidone	Homo sapiens (human)	IC50	0.0167	3	2
risperidone	Homo sapiens (human)	Ki	0.0038	16	15
ropinirole	Homo sapiens (human)	Ki	0.3495	2	2
salmeterol xinafoate	Homo sapiens (human)	Ki	32.0000	1	1
sb 206553	Homo sapiens (human)	Ki	10.0000	1	1
spiperone	Homo sapiens (human)	IC50	0.0008	2	2
spiperone	Homo sapiens (human)	Ki	0.0004	11	12
sulpiride	Homo sapiens (human)	IC50	0.0858	3	2
sulpiride	Homo sapiens (human)	Ki	0.0659	3	2
sumatriptan	Homo sapiens (human)	Ki	0.2180	1	1
terfenadine	Homo sapiens (human)	IC50	6.1670	1	0
terfenadine	Homo sapiens (human)	Ki	2.0560	1	0
thioridazine	Homo sapiens (human)	IC50	0.0350	1	0
thioridazine	Homo sapiens (human)	Ki	0.0157	3	2
tiapride	Homo sapiens (human)	IC50	1.2320	1	0
tiapride	Homo sapiens (human)	Ki	0.4110	1	0
trazodone	Homo sapiens (human)	IC50	4.4850	1	1
tyramine	Homo sapiens (human)	Ki	160.0000	1	1
zotepine	Homo sapiens (human)	Ki	0.0120	2	2
lysergic acid diethylamide	Homo sapiens (human)	Ki	0.1229	2	2
apomorphine	Homo sapiens (human)	IC50	0.0146	2	2
apomorphine	Homo sapiens (human)	Ki	0.0598	20	20
chlorpromazine hydrochloride	Homo sapiens (human)	Ki	0.0030	1	1
phenyltoloxamine	Homo sapiens (human)	Ki	2.7400	1	1
ergotamine	Homo sapiens (human)	IC50	0.0043	1	0
ergotamine	Homo sapiens (human)	Ki	0.0014	1	0
methylergonovine	Homo sapiens (human)	IC50	0.8290	1	0
methylergonovine	Homo sapiens (human)	Ki	0.2760	1	0
dibenzothiazyl disulfide	Homo sapiens (human)	IC50	5.8660	1	0
dibenzothiazyl disulfide	Homo sapiens (human)	Ki	1.9550	1	0
yohimbine	Homo sapiens (human)	IC50	2.0600	1	0
yohimbine	Homo sapiens (human)	Ki	0.6870	1	0
indopan	Homo sapiens (human)	Ki	10.0000	1	1
dibenzepin	Homo sapiens (human)	Ki	30.2000	1	1
methysergide	Homo sapiens (human)	IC50	0.8070	1	0
methysergide	Homo sapiens (human)	Ki	0.2690	1	0
normethadone	Homo sapiens (human)	Ki	34.9000	1	1
dihydroergotamine	Homo sapiens (human)	IC50	0.0089	1	0
dihydroergotamine	Homo sapiens (human)	Ki	0.0030	1	0
gentian violet	Homo sapiens (human)	IC50	3.1780	1	0
gentian violet	Homo sapiens (human)	Ki	1.0590	1	0
3-tyramine	Homo sapiens (human)	Ki	20.0000	1	1
azaperone	Homo sapiens (human)	Ki	0.1934	3	5
11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine	Homo sapiens (human)	Ki	2.5000	1	1
2-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine	Homo sapiens (human)	IC50	0.0340	1	1
2-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine	Homo sapiens (human)	Ki	0.0470	1	1
pimozide	Homo sapiens (human)	Ki	0.0118	2	2
benperidol	Homo sapiens (human)	Ki	0.0000	1	1
canadine, (s)-isomer	Homo sapiens (human)	Ki	0.0996	2	2
clemastine	Homo sapiens (human)	IC50	0.1360	1	0
clemastine	Homo sapiens (human)	Ki	0.0450	1	0
pizotyline	Homo sapiens (human)	Ki	0.0024	1	1
metergoline	Homo sapiens (human)	IC50	0.0630	1	0
metergoline	Homo sapiens (human)	Ki	0.0210	1	0
lisuride	Homo sapiens (human)	IC50	0.0029	1	0
lisuride	Homo sapiens (human)	Ki	0.0007	4	4
bromocriptine	Homo sapiens (human)	IC50	0.0016	1	0
bromocriptine	Homo sapiens (human)	Ki	0.0101	3	3
1-(3-chloro-5-benzo[b][1]benzoxepinyl)-4-methylpiperazine	Homo sapiens (human)	Ki	0.0025	2	2
penfluridol	Homo sapiens (human)	Ki	0.1590	1	1
butaclamol	Homo sapiens (human)	IC50	0.0023	3	3
butaclamol	Homo sapiens (human)	Ki	0.0001	3	3
butaclamol	Homo sapiens (human)	IC50	0.0123	8	8
butaclamol	Homo sapiens (human)	Ki	0.0014	5	5
4-(4-chlorophenyl)-4-hydroxypiperidine	Homo sapiens (human)	Ki	9.1051	1	2
indalpine	Homo sapiens (human)	Ki	1.0000	1	1
pergolide	Homo sapiens (human)	IC50	0.1110	1	0
pergolide	Homo sapiens (human)	Ki	0.0285	4	4
haloperidol decanoate	Homo sapiens (human)	Ki	0.0011	2	2
remoxipride	Homo sapiens (human)	IC50	0.4406	2	2
remoxipride	Homo sapiens (human)	Ki	0.2170	1	1
quinpirole	Homo sapiens (human)	Ki	1.9809	29	29
gepirone	Homo sapiens (human)	Ki	2.1890	2	2
ipsapirone	Homo sapiens (human)	Ki	0.8527	3	3
eticlopride	Homo sapiens (human)	IC50	10.0000	1	1
eticlopride	Homo sapiens (human)	Ki	0.0002	3	3
mk 458	Homo sapiens (human)	Ki	0.0115	4	7
naxagolide	Homo sapiens (human)	Ki	0.0063	2	2
n 0437, (-)-isomer	Homo sapiens (human)	Ki	0.0067	3	3
sertindole	Homo sapiens (human)	Ki	0.0028	3	3
fananserin	Homo sapiens (human)	Ki	0.5900	2	2
aripiprazole	Homo sapiens (human)	IC50	0.0158	4	5
aripiprazole	Homo sapiens (human)	Ki	0.0020	34	35
ziprasidone	Homo sapiens (human)	IC50	0.0050	1	1
ziprasidone	Homo sapiens (human)	Ki	0.0042	12	13
dopamine hydrochloride	Homo sapiens (human)	IC50	50.5000	2	2
dopamine hydrochloride	Homo sapiens (human)	Ki	2.1592	6	9
halopemide	Homo sapiens (human)	IC50	0.0070	1	1
spiramide	Homo sapiens (human)	Ki	0.0030	1	1
oxiperomide	Homo sapiens (human)	Ki	0.0055	1	1
mezilamine	Homo sapiens (human)	Ki	0.0054	1	1
hp 873	Homo sapiens (human)	IC50	0.1100	1	1
tetrahydropalmatine	Homo sapiens (human)	IC50	0.4500	1	1
tetrahydropalmatine	Homo sapiens (human)	Ki	3.0625	2	2
ergocornine	Homo sapiens (human)	IC50	0.0050	1	0
ergocornine	Homo sapiens (human)	Ki	0.0017	1	0
tandospirone	Homo sapiens (human)	Ki	0.4600	1	1
salsolinol	Homo sapiens (human)	Ki	5.0000	1	1
msh release-inhibiting hormone	Homo sapiens (human)	Ki	0.0340	7	8
fla 797	Homo sapiens (human)	IC50	0.0100	1	1
1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)quinolizine	Homo sapiens (human)	Ki	10.0000	1	1
gr 127935	Homo sapiens (human)	Ki	10.0000	2	2
ecopipam	Homo sapiens (human)	Ki	1.0667	3	3
3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide	Homo sapiens (human)	Ki	0.0042	2	2
pd 128907	Homo sapiens (human)	Ki	8.7900	2	2
paliperidone	Homo sapiens (human)	IC50	0.0083	1	1
3-n-methylspiperone	Homo sapiens (human)	Ki	0.0001	1	1
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol	Homo sapiens (human)	Ki	0.0912	1	1
pramipexole	Homo sapiens (human)	IC50	10.0000	1	1
pramipexole	Homo sapiens (human)	Ki	1.0903	17	17
sb 204070a	Homo sapiens (human)	Ki	10.0000	1	1
2-(n,n-dimethylamino)-6,7-dihydroxytetralin	Homo sapiens (human)	Ki	0.3400	1	1
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin	Homo sapiens (human)	Ki	0.2170	1	1
uh 301	Homo sapiens (human)	Ki	3.7600	1	1
aj 76	Homo sapiens (human)	Ki	0.0140	1	1
1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine	Homo sapiens (human)	Ki	0.0198	3	3
11-hydroxy-n-(n-propyl)noraporphine	Homo sapiens (human)	Ki	0.8540	1	1
1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine	Homo sapiens (human)	Ki	10.0000	1	1
n 0734	Homo sapiens (human)	Ki	0.0121	2	2
tamsulosin	Homo sapiens (human)	Ki	0.0455	2	2
3-propylamino-5-hydroxychroman	Homo sapiens (human)	Ki	3.0000	1	1
5-(dipropylamino)-5,6-dihydro-4h-imidazo-(5,1ij)quinolin-2(1h)-one	Homo sapiens (human)	Ki	0.0066	2	2
sc 53116	Homo sapiens (human)	IC50	10.0000	1	1
sc 53116	Homo sapiens (human)	Ki	10.0000	1	1
dc 015	Homo sapiens (human)	Ki	0.1985	2	2
u-91356	Homo sapiens (human)	Ki	0.8118	3	3
l 741742	Homo sapiens (human)	Ki	1.7000	4	4
sonepiprazole	Homo sapiens (human)	Ki	5.1470	1	1
l 741626	Homo sapiens (human)	IC50	0.0045	1	1
l 741626	Homo sapiens (human)	Ki	0.0089	6	6
alpha-ergocryptine	Homo sapiens (human)	IC50	0.0020	1	0
alpha-ergocryptine	Homo sapiens (human)	Ki	0.0006	1	0
sk&f-38393	Homo sapiens (human)	Ki	4.4800	2	2
chloroethylnorapomorphine	Homo sapiens (human)	IC50	8.0000	1	1
harmalan	Homo sapiens (human)	Ki	10.0000	1	1
corydalmine	Homo sapiens (human)	IC50	18.7300	1	1
corydalmine	Homo sapiens (human)	Ki	0.4190	2	2
n-n-propylnorapomorphine	Homo sapiens (human)	IC50	0.0000	1	1
n-n-propylnorapomorphine	Homo sapiens (human)	Ki	0.0500	1	1
n-demethyllysergic acid diethylamide	Homo sapiens (human)	IC50	10.0000	1	1
4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine	Homo sapiens (human)	Ki	0.0100	1	1
5-hydroxy-2-n,n-dipropylaminotetralin	Homo sapiens (human)	Ki	0.0374	4	4
1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine	Homo sapiens (human)	Ki	0.0975	2	2
piboserod	Homo sapiens (human)	Ki	1.0000	1	1
nantenine, (+-)-isomer	Homo sapiens (human)	Ki	0.8580	1	1
sibenadet	Homo sapiens (human)	IC50	0.1000	1	1
ngd 94-1	Homo sapiens (human)	Ki	2.2400	2	2
maduramicin	Homo sapiens (human)	IC50	0.7020	1	0
maduramicin	Homo sapiens (human)	Ki	0.2340	1	0
latrepirdine	Homo sapiens (human)	Ki	0.6310	1	1
bifeprunox	Homo sapiens (human)	IC50	0.0029	1	1
bifeprunox	Homo sapiens (human)	Ki	0.0023	7	8
lurasidone	Homo sapiens (human)	Ki	0.0017	1	1
1-methyl-6-methoxy-dihydro-beta-carboline	Homo sapiens (human)	Ki	10.0000	1	1
discretamine	Homo sapiens (human)	Ki	0.2140	1	1
tetrahydrocolumbamine	Homo sapiens (human)	Ki	0.0664	2	2
sb 243213	Homo sapiens (human)	IC50	1.0000	1	1
ergonovine	Homo sapiens (human)	IC50	0.5520	1	0
ergonovine	Homo sapiens (human)	Ki	0.1840	1	0
darifenacin	Homo sapiens (human)	IC50	25.1189	1	1
dihydroergocristine monomesylate	Homo sapiens (human)	IC50	0.0015	1	0
dihydroergocristine monomesylate	Homo sapiens (human)	Ki	0.0005	1	0
diethylstilbestrol	Homo sapiens (human)	IC50	13.3210	1	0
diethylstilbestrol	Homo sapiens (human)	Ki	4.4400	1	0
chlorprothixene	Homo sapiens (human)	Ki	0.0030	1	1
levosulpiride	Homo sapiens (human)	IC50	0.0640	2	1
levosulpiride	Homo sapiens (human)	Ki	0.0770	5	4
4,4-dicarboxy-5-pyridoxylproline	Homo sapiens (human)	Ki	0.8152	2	3
flunarizine	Homo sapiens (human)	IC50	0.3520	1	0
flunarizine	Homo sapiens (human)	Ki	0.1170	1	0
cinnarizine	Homo sapiens (human)	IC50	0.7760	1	0
cinnarizine	Homo sapiens (human)	Ki	0.2590	1	0
tamoxifen	Homo sapiens (human)	IC50	13.8850	1	0
tamoxifen	Homo sapiens (human)	Ki	4.6280	1	0
altanserin	Homo sapiens (human)	Ki	0.0620	1	1
raclopride	Homo sapiens (human)	IC50	0.0520	2	4
raclopride	Homo sapiens (human)	Ki	0.0149	5	5
sch 23390	Homo sapiens (human)	IC50	1.0405	2	2
sch 23390	Homo sapiens (human)	Ki	0.9456	2	2
bp 897	Homo sapiens (human)	Ki	0.1374	11	11
pm 1000	Homo sapiens (human)	Ki	1.0700	2	2
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea	Homo sapiens (human)	Ki	31.6228	1	1
sb-224289	Homo sapiens (human)	Ki	1.0000	1	1
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide	Homo sapiens (human)	IC50	1.0000	1	1
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide	Homo sapiens (human)	Ki	1.9000	2	2
pd 168,077	Homo sapiens (human)	IC50	10.0000	1	1
pd 168,077	Homo sapiens (human)	Ki	2.7397	5	5
le 300	Homo sapiens (human)	Ki	0.0356	6	6
abt724	Homo sapiens (human)	Ki	22.0533	3	3
harmine	Homo sapiens (human)	Ki	10.0000	1	1
sb 277011	Homo sapiens (human)	Ki	0.9301	13	13
preclamol	Homo sapiens (human)	Ki	0.3580	7	7
l 745870	Homo sapiens (human)	Ki	18.2739	18	18
mdl 100907	Homo sapiens (human)	Ki	1.5375	4	4
pd 128907	Homo sapiens (human)	Ki	1.8856	5	6
sb 258719	Homo sapiens (human)	Ki	3.9810	2	3
sb 271046	Homo sapiens (human)	Ki	1.8279	2	3
8-hydroxy-2-(n-n-propyl-n-(3'-iodo-2'-propenyl)amino)tetralin	Homo sapiens (human)	Ki	1.0720	1	1
gr 46611	Homo sapiens (human)	Ki	1.0000	1	1
7-hydroxy-2-(n-n-propyl-n-(3-iodo-2'-propenyl)-amino)tetralin	Homo sapiens (human)	Ki	0.1358	2	2
a 77636	Homo sapiens (human)	Ki	1.5500	1	1
dihydrexidine	Homo sapiens (human)	Ki	1.2742	6	6
8-hydroxy-2-(di-n-propylamino)tetralin, (r)-isomer	Homo sapiens (human)	Ki	0.3538	4	4
7-hydroxy-2-n,n-dipropylaminotetralin, (r)-isomer	Homo sapiens (human)	Ki	0.0947	6	6
l 750667	Homo sapiens (human)	Ki	1.7000	1	1
uh 232	Homo sapiens (human)	Ki	0.0130	1	1
sb 269970	Homo sapiens (human)	Ki	0.3161	2	2
sk&f-38393	Homo sapiens (human)	Ki	7.1100	2	2
stepholidine	Homo sapiens (human)	IC50	2.2427	2	2
stepholidine	Homo sapiens (human)	Ki	0.4241	5	5
vilazodone	Homo sapiens (human)	Ki	0.6660	1	1
sarizotan	Homo sapiens (human)	IC50	0.0060	1	1
ms-245	Homo sapiens (human)	Ki	0.2100	1	1
n-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide	Homo sapiens (human)	Ki	5.0119	1	1
armodafinil	Homo sapiens (human)	IC50	0.0021	1	1
armodafinil	Homo sapiens (human)	Ki	100.0000	1	1
pridopidine	Homo sapiens (human)	Ki	12.5178	4	4
osu 6162	Homo sapiens (human)	Ki	1.3258	4	4
pnu-95666	Homo sapiens (human)	Ki	4.0931	4	4
cp 293019	Homo sapiens (human)	Ki	3.3100	2	2
n-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide	Homo sapiens (human)	IC50	0.0920	1	1
n-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide	Homo sapiens (human)	Ki	0.0339	4	4
2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena(c)phenanthrene-9,10-diol	Homo sapiens (human)	Ki	0.7100	2	2
sb258741	Homo sapiens (human)	Ki	1.5849	1	1
f 13640	Homo sapiens (human)	Ki	30.5000	2	2
s 33084	Homo sapiens (human)	Ki	0.0316	1	1
yf 476	Homo sapiens (human)	Ki	0.0288	1	1
slv 313	Homo sapiens (human)	Ki	0.0062	2	2
fauc 346	Homo sapiens (human)	Ki	0.0697	6	6
ngb 2904	Homo sapiens (human)	IC50	1.2800	2	2
ngb 2904	Homo sapiens (human)	Ki	0.1912	8	8
u 92016a	Homo sapiens (human)	Ki	0.0350	1	1
4-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-1-(4-fluorophenyl)butan-1-one	Homo sapiens (human)	Ki	0.2227	3	5
flb 457	Homo sapiens (human)	Ki	0.0000	1	1
pnu 109291	Homo sapiens (human)	Ki	0.2410	2	2
pnu 96415e	Homo sapiens (human)	Ki	0.1990	1	1
sb 269,652	Homo sapiens (human)	Ki	0.4850	1	1
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride	Homo sapiens (human)	Ki	0.5385	2	2
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	Homo sapiens (human)	IC50	10.0000	1	1
n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide	Homo sapiens (human)	IC50	0.0050	1	1
n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide	Homo sapiens (human)	Ki	0.0015	3	3
tert-butyl peroxybenzoate	Homo sapiens (human)	IC50	3.8750	2	2
opc-14857	Homo sapiens (human)	Ki	0.0073	1	1
77-lh-28-1	Homo sapiens (human)	Ki	0.6761	2	2
fauc 365	Homo sapiens (human)	IC50	0.0947	1	1
fauc 365	Homo sapiens (human)	Ki	2.3541	13	13
sb-649915	Homo sapiens (human)	Ki	1.2589	1	1
11-hydroxy-n-(n-propyl)noraporphine hydrochloride, (r)-isomer	Homo sapiens (human)	Ki	3.3756	3	3
fauc 213	Homo sapiens (human)	Ki	7.0785	14	14
way-208466	Homo sapiens (human)	IC50	5.0000	1	1
9-(aminomethyl)-9,10-dihydroanthracene	Homo sapiens (human)	Ki	10.0000	1	1
fauc 113	Homo sapiens (human)	Ki	3.4546	15	15
desmethoxyfallypride	Homo sapiens (human)	Ki	0.0300	2	2
2-(3',4',5',6'-tetrahydro-2'h-(2,4') bipyridinyl-1'-yl)-n-m-tolyl-acetamide	Homo sapiens (human)	IC50	27.9230	2	2
2-(3',4',5',6'-tetrahydro-2'h-(2,4') bipyridinyl-1'-yl)-n-m-tolyl-acetamide	Homo sapiens (human)	Ki	3.1337	3	3
(5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol	Homo sapiens (human)	Ki	0.3500	1	1
1-(2,4-difluorophenethyl)-4-(4-fluorophenylsulfonyl)piperidine	Homo sapiens (human)	Ki	1.3333	3	3
cariprazine	Homo sapiens (human)	IC50	0.0017	1	2
cariprazine	Homo sapiens (human)	Ki	0.0092	12	14
naphyrone	Homo sapiens (human)	IC50	10.0000	1	1
amd 070	Homo sapiens (human)	IC50	4.1000	1	1
sb 742457	Homo sapiens (human)	Ki	0.9970	2	2
5-hydroxy-2-n,n-dipropylaminotetralin, (s)-isomer	Homo sapiens (human)	Ki	0.0090	3	3
naluzotan	Homo sapiens (human)	Ki	2.0000	2	2
pg 01037	Homo sapiens (human)	IC50	0.0809	2	2
pg 01037	Homo sapiens (human)	Ki	0.0922	6	6
snap7941	Homo sapiens (human)	Ki	2.8000	1	1
le 404	Homo sapiens (human)	Ki	0.0207	5	5
gsk598809	Homo sapiens (human)	Ki	2.1100	1	1
7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide	Homo sapiens (human)	Ki	1.4300	1	1
brexpiprazole	Homo sapiens (human)	Ki	0.0004	3	4
octoclothepine, (s)-isomer	Homo sapiens (human)	Ki	0.0011	1	1
a 803467	Homo sapiens (human)	IC50	10.0000	1	1
sp 203	Homo sapiens (human)	Ki	10.0000	1	1
lu ae58054	Homo sapiens (human)	Ki	1.2150	1	1
n-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide	Homo sapiens (human)	Ki	0.1753	3	3
nitd 609	Homo sapiens (human)	IC50	10.0000	1	1
mk-7246	Homo sapiens (human)	Ki	3.8244	2	0
n,n-diallyl-5-methoxytryptamine	Homo sapiens (human)	Ki	10.0000	2	2
vu0364572	Homo sapiens (human)	IC50	30.0000	1	1
3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol	Homo sapiens (human)	IC50	1.6470	1	1
3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol	Homo sapiens (human)	Ki	0.4500	1	1
azd3759	Homo sapiens (human)	IC50	0.7970	1	1
clozapine	Homo sapiens (human)	IC50	0.2044	8	8
clozapine	Homo sapiens (human)	Ki	0.1296	69	70
olanzapine	Homo sapiens (human)	IC50	0.1180	1	0
olanzapine	Homo sapiens (human)	Ki	0.0329	22	23
norclozapine	Homo sapiens (human)	Ki	0.4890	1	1

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
7-hydroxy-2-n,n-dipropylaminotetralin	Homo sapiens (human)	EC50	0.0398	1	1
haloperidol	Homo sapiens (human)	Kd	0.0005	1	1
moperone	Homo sapiens (human)	Kd	0.0010	1	1
propranolol	Homo sapiens (human)	EC50	5.0119	1	1
ropinirole	Homo sapiens (human)	EC50	0.1911	12	13
spiperone	Homo sapiens (human)	Kd	0.0001	2	2
sulpiride	Homo sapiens (human)	Kd	0.0028	1	1
apomorphine	Homo sapiens (human)	EC50	0.0544	10	11
apomorphine	Homo sapiens (human)	Kd	0.0240	1	1
pimozide	Homo sapiens (human)	Kd	0.0290	1	1
lisuride	Homo sapiens (human)	EC50	0.0000	1	0
bromocriptine	Homo sapiens (human)	EC50	0.0005	1	0
pergolide	Homo sapiens (human)	EC50	0.0004	1	0
quinpirole	Homo sapiens (human)	EC50	0.3088	55	62
quinelorane	Homo sapiens (human)	EC50	0.0306	2	3
n 0437, (-)-isomer	Homo sapiens (human)	EC50	0.0031	4	4
aripiprazole	Homo sapiens (human)	EC50	0.8222	23	28
dopamine hydrochloride	Homo sapiens (human)	EC50	0.0006	1	1
msh release-inhibiting hormone	Homo sapiens (human)	EC50	0.1700	1	1
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol	Homo sapiens (human)	Kd	0.0912	1	1
pramipexole	Homo sapiens (human)	EC50	0.0260	7	6
pramipexole	Homo sapiens (human)	Kd	0.0000	2	2
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin	Homo sapiens (human)	EC50	0.0007	1	1
5-(dipropylamino)-5,6-dihydro-4h-imidazo-(5,1ij)quinolin-2(1h)-one	Homo sapiens (human)	EC50	0.0025	1	1
u-91356	Homo sapiens (human)	EC50	0.0460	6	6
l 741626	Homo sapiens (human)	EC50	0.0045	1	1
10,11-methylenedioxy-n-propylnoraporphine	Homo sapiens (human)	EC50	0.2592	2	4
sk&f 89124	Homo sapiens (human)	EC50	0.0018	1	2
n-n-propylnorapomorphine	Homo sapiens (human)	EC50	0.0055	3	5
n-n-propylnorapomorphine	Homo sapiens (human)	Kd	0.0200	1	1
4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine	Homo sapiens (human)	Kd	0.0100	1	1
5-hydroxy-2-n,n-dipropylaminotetralin	Homo sapiens (human)	EC50	0.0258	2	2
1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine	Homo sapiens (human)	Kd	0.0050	1	1
zm 241385	Homo sapiens (human)	EC50	100.0000	1	1
sibenadet	Homo sapiens (human)	EC50	0.0032	2	2
roxindole	Homo sapiens (human)	EC50	0.0004	1	1
darifenacin	Homo sapiens (human)	EC50	10.0000	1	1
pd 168,077	Homo sapiens (human)	EC50	10.0000	1	1
preclamol	Homo sapiens (human)	EC50	0.4610	3	3
a 77636	Homo sapiens (human)	EC50	4.0000	1	1
dihydrexidine	Homo sapiens (human)	EC50	1.6100	1	1
sk&f-38393	Homo sapiens (human)	EC50	7.5000	2	2
sk&f-38393	Homo sapiens (human)	Kd	9.5000	1	1
indacaterol	Homo sapiens (human)	EC50	10.0000	1	1
pnu-95666	Homo sapiens (human)	EC50	0.1807	8	8
n-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide	Homo sapiens (human)	EC50	0.0920	1	1
2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena(c)phenanthrene-9,10-diol	Homo sapiens (human)	EC50	3.9000	1	1
opc-14857	Homo sapiens (human)	EC50	0.0822	2	2
cariprazine	Homo sapiens (human)	EC50	0.0176	6	15
5-hydroxy-2-n,n-dipropylaminotetralin, (s)-isomer	Homo sapiens (human)	EC50	0.0410	1	1
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride	Homo sapiens (human)	Kd	0.0043	1	1
brexpiprazole	Homo sapiens (human)	EC50	0.0118	3	5
3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol	Homo sapiens (human)	EC50	10.0000	1	1

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
1-(2-methoxyphenyl)piperazine	Homo sapiens (human)	Kb	0.4790	1	1
chlorpromazine	Homo sapiens (human)	Kb	0.3341	3	3
haloperidol	Homo sapiens (human)	Kb	0.0014	1	1
haloperidol	Homo sapiens (human)	pKi	0.0091	1	1
sulpiride	Homo sapiens (human)	Kb	0.0030	1	1
apomorphine	Homo sapiens (human)	ID50	0.0390	1	1
apomorphine	Homo sapiens (human)	KL	0.1665	2	2
metergoline	Homo sapiens (human)	Activity	0.0740	1	1
butaclamol	Homo sapiens (human)	Kb	0.0004	1	1
ziprasidone	Homo sapiens (human)	Activity	0.0097	1	1
sb 277011	Homo sapiens (human)	Kb	6.4900	1	1
preclamol	Homo sapiens (human)	Ke	0.3723	3	3
dihydrexidine	Homo sapiens (human)	K0.5	0.0877	1	1
vuf 2274	Homo sapiens (human)	Activity	2.0000	1	1
4-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-1-(4-fluorophenyl)butan-1-one	Homo sapiens (human)	pKi	0.0075	1	1
sb 269,652	Homo sapiens (human)	Kb	1.0386	5	5
clozapine	Homo sapiens (human)	Activity	0.2560	1	1
clozapine	Homo sapiens (human)	Kb	10.0000	1	1
clozapine	Homo sapiens (human)	pKi	0.0069	1	1

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010

Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
Journal of medicinal chemistry, , May-22, Volume: 51, Issue:10, 2008

Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
Journal of medicinal chemistry, , Nov-25, Volume: 37, Issue:24, 1994

Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
Journal of medicinal chemistry, , Oct-15, Volume: 36, Issue:21, 1993

Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.
Bioorganic & medicinal chemistry letters, , Mar-06, Volume: 10, Issue:5, 2000

New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
Journal of medicinal chemistry, , Mar-14, Volume: 40, Issue:6, 1997

Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
Journal of medicinal chemistry, , Oct-15, Volume: 36, Issue:21, 1993

Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives.
Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993

Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993

Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.
Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996

'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009

Designed multiple ligands. An emerging drug discovery paradigm.
Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
Journal of medicinal chemistry, , Aug-09, Volume: 55, Issue:15, 2012

[no title available]
European journal of medicinal chemistry, , May-05, Volume: 235, 2022

Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001

Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

[no title available]
,

Chemical update on the potential for serotonin 5-HT
Bioorganic & medicinal chemistry letters, , 10-01, Volume: 49, 2021

Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
European journal of medicinal chemistry, , Nov-10, Volume: 123, 2016

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009

[no title available]
,

[no title available]
,

Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists.
Journal of medicinal chemistry, , Apr-21, Volume: 48, Issue:8, 2005

Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
Bioorganic & medicinal chemistry letters, , 11-01, Volume: 29, Issue:21, 2019

Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Journal of medicinal chemistry, , 03-22, Volume: 61, Issue:6, 2018

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006

New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
Journal of medicinal chemistry, , Mar-14, Volume: 40, Issue:6, 1997

(R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridines: novel optically active compounds with strong 5-HT1A receptor binding ability exhibiting anticonflict activity and lessening of memory impairment.
Journal of medicinal chemistry, , Nov-12, Volume: 36, Issue:23, 1993

Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993

[no title available]
,

[no title available]
,

[no title available]
Journal of medicinal chemistry, , 09-09, Volume: 64, Issue:17, 2021

Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
European journal of medicinal chemistry, , Mar-15, Volume: 166, 2019

Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
European journal of medicinal chemistry, , Oct-15, Volume: 180, 2019

[no title available]
Bioorganic & medicinal chemistry letters, , 06-15, Volume: 28, Issue:11, 2018

Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015

Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding?
Journal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014

Polypharmacology - foe or friend?
Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 20, Issue:21, 2012

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
Journal of medicinal chemistry, , Nov-16, Volume: 49, Issue:23, 2006

Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists.
Journal of medicinal chemistry, , Volume: 24, Issue:6, 1981

[no title available]
,

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

[no title available]
,

Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid.
Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 13, Issue:19, 2003

[no title available]
,

Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
Bioorganic & medicinal chemistry letters, , May-03, Volume: 14, Issue:9, 2004

[no title available]
,

[no title available]
,

Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).
Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985

[no title available]
,

New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists.
Journal of medicinal chemistry, , Sep-29, Volume: 38, Issue:20, 1995

[no title available]
,

[no title available]
,

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

[no title available]
Journal of medicinal chemistry, , 06-10, Volume: 64, Issue:11, 2021

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009

[no title available]
,

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 21, Issue:15, 2011

[no title available]
Bioorganic & medicinal chemistry letters, , 06-15, Volume: 28, Issue:11, 2018

Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
Journal of medicinal chemistry, , Volume: 34, Issue:10, 1991

Polypharmacology - foe or friend?
Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013

Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
Bioorganic & medicinal chemistry letters, , May-03, Volume: 14, Issue:9, 2004

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Journal of medicinal chemistry, , Nov-07, Volume: 45, Issue:23, 2002

Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.
Bioorganic & medicinal chemistry letters, , Mar-06, Volume: 10, Issue:5, 2000

[no title available]
Journal of medicinal chemistry, , 06-10, Volume: 64, Issue:11, 2021

New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Journal of medicinal chemistry, , Jun-17, Volume: 42, Issue:12, 1999

Binding of 5H-dibenzo[a,d]cycloheptene and dibenz[b,f]oxepin analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Feb-17, Volume: 38, Issue:4, 1995

Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009

[no title available]
,

[no title available]
Journal of medicinal chemistry, , 06-10, Volume: 64, Issue:11, 2021

[no title available]
,

Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005

Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.
Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002

Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.
Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002

[no title available]
,

Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005

Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.
European journal of medicinal chemistry, , Dec-15, Volume: 208, 2020

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

New tetrahydroisoquinoline-based D
Bioorganic & medicinal chemistry letters, , 06-15, Volume: 42, 2021

Novel D
European journal of medicinal chemistry, , Mar-15, Volume: 232, 2022

Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

[no title available]
,

Polypharmacology - foe or friend?
Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013

[no title available]
,

Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.
Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23, 2015

[no title available]
Journal of medicinal chemistry, , 09-09, Volume: 64, Issue:17, 2021

Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Bioorganic & medicinal chemistry, , 09-15, Volume: 24, Issue:18, 2016

Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008

Selective optimization of side activities: another way for drug discovery.
Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004

Current and novel approaches to the drug treatment of schizophrenia.
Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Bioorganic & medicinal chemistry letters, , May-21, Volume: 11, Issue:10, 2001

[no title available]
,

Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.
Chemical biology & drug design, , Volume: 88, Issue:4, 2016

[no title available]
,

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
Journal of medicinal chemistry, , 06-08, Volume: 60, Issue:11, 2017

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
Journal of medicinal chemistry, , Jan-22, Volume: 58, Issue:2, 2015

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010

Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 18, Issue:15, 2010

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist.
Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985

[no title available]
,

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.
Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995

[no title available]
Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019

Highly Selective Dopamine D
Journal of medicinal chemistry, , 12-14, Volume: 60, Issue:23, 2017

Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.
Chemical biology & drug design, , Volume: 88, Issue:4, 2016

Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.
Bioorganic & medicinal chemistry, , 08-15, Volume: 24, Issue:16, 2016

Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015

Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 23, Issue:6, 2013

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012

Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
Bioorganic & medicinal chemistry, , Jul-15, Volume: 16, Issue:14, 2008

Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

The role of receptor binding in drug discovery.
Journal of natural products, , Volume: 56, Issue:4, 1993

Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993

Chemical update on the potential for serotonin 5-HT
Bioorganic & medicinal chemistry letters, , 10-01, Volume: 49, 2021

Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D
Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020

[no title available]
Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
Journal of medicinal chemistry, , May-26, Volume: 54, Issue:10, 2011

Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

[no title available]
,

Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998

[no title available]
,

Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
European journal of medicinal chemistry, , Sep-01, Volume: 201, 2020

Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003

[no title available]
,

[no title available]
,

Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
Bioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Selective optimization of side activities: another way for drug discovery.
Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004

Current and novel approaches to the drug treatment of schizophrenia.
Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001

A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003

Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
Journal of medicinal chemistry, , Sep-12, Volume: 45, Issue:19, 2002

Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993

Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity.
Journal of medicinal chemistry, , Aug-12, Volume: 47, Issue:17, 2004

[no title available]
,

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.
Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020

[no title available]
,

[no title available]
Journal of medicinal chemistry, , 06-10, Volume: 64, Issue:11, 2021

[no title available]
,

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

A study of the structure-affinity relationship in SYA16263; is a D
Bioorganic & medicinal chemistry, , 01-15, Volume: 30, 2021

New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021

Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors.
Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993

Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Journal of medicinal chemistry, , Jun-17, Volume: 42, Issue:12, 1999

Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012

Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
Bioorganic & medicinal chemistry, , Aug-15, Volume: 18, Issue:16, 2010

Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003

Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.
Bioorganic & medicinal chemistry, , 08-15, Volume: 24, Issue:16, 2016

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.
Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

[no title available]
,

Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 21, Issue:24, 2013

Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates.
Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010

[no title available]
,

Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

[no title available]
,

Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

[no title available]
,

Binding of 5H-dibenzo[a,d]cycloheptene and dibenz[b,f]oxepin analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Feb-17, Volume: 38, Issue:4, 1995

Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.
Bioorganic & medicinal chemistry letters, , 12-15, Volume: 28, Issue:23-24, 2018

Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.
Journal of medicinal chemistry, , 01-12, Volume: 60, Issue:1, 2017

Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bioorganic & medicinal chemistry, , Apr-15, Volume: 24, Issue:8, 2016

Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015

Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.
Bioorganic & medicinal chemistry letters, , Feb-10, Volume: 13, Issue:3, 2003

Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

[no title available]
,

Synthesis and binding profile of haloperidol-based bivalent ligands targeting dopamine D(2)-like receptors.
Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 24, Issue:16, 2014

QSAR prediction of D2 receptor antagonistic activity of 6-methoxy benzamides.
European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010

trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents.
Journal of medicinal chemistry, , Oct-19, Volume: 43, Issue:21, 2000

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Journal of medicinal chemistry, , 03-22, Volume: 61, Issue:6, 2018

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006

Radioligand and computational insight in structure - Activity relationship of saccharin derivatives being ipsapirone and revospirone analogues.
Bioorganic & medicinal chemistry letters, , 06-15, Volume: 42, 2021

Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
Bioorganic & medicinal chemistry letters, , 11-01, Volume: 29, Issue:21, 2019

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
Journal of medicinal chemistry, , Jan-22, Volume: 58, Issue:2, 2015

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007

[no title available]
Journal of medicinal chemistry, , 10-28, Volume: 64, Issue:20, 2021

Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.
Journal of medicinal chemistry, , 12-08, Volume: 59, Issue:23, 2016

Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state.
Journal of medicinal chemistry, , Jan-23, Volume: 57, Issue:2, 2014

Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 19, Issue:17, 2009

Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
Journal of medicinal chemistry, , 06-08, Volume: 60, Issue:11, 2017

Synthesis and SAR study of a novel series of dopamine receptor agonists.
Bioorganic & medicinal chemistry, , Jan-01, Volume: 22, Issue:1, 2014

Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety.
Journal of medicinal chemistry, , Jul-04, Volume: 45, Issue:14, 2002

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996

Discovery of novel α₁-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands.
Bioorganic & medicinal chemistry, , Jan-01, Volume: 21, Issue:1, 2013

Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.
Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010

Selective optimization of side activities: another way for drug discovery.
Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004

4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.
Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002

Current and novel approaches to the drug treatment of schizophrenia.
Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001

[no title available]
European journal of medicinal chemistry, , Jan-01, Volume: 185, 2020

[no title available]
European journal of medicinal chemistry, , May-15, Volume: 170, 2019

2-Aminoimidazole-based antagonists of the 5-HT
European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019

[no title available]
Journal of medicinal chemistry, , Aug-09, Volume: 61, Issue:15, 2018

[no title available]
European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018

[no title available]
ACS medicinal chemistry letters, , Apr-13, Volume: 8, Issue:4, 2017

Polypharmacology - foe or friend?
Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013

Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012

1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 18, Issue:2, 2008

Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Designed multiple ligands. An emerging drug discovery paradigm.
Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005

Selective optimization of side activities: another way for drug discovery.
Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004

Current and novel approaches to the drug treatment of schizophrenia.
Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001

Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state.
Journal of medicinal chemistry, , Jan-23, Volume: 57, Issue:2, 2014

Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.
Journal of medicinal chemistry, , Mar-28, Volume: 56, Issue:6, 2013

Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993

Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 22, Issue:15, 2012

Conformational analysis of tandospirone in aqueous solution: lead evolution of potent dopamine D4 receptor ligands.
Bioorganic & medicinal chemistry letters, , May-07, Volume: 11, Issue:9, 2001

3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995

Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.
Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

[no title available]
,

Conformational analysis of tandospirone in aqueous solution: lead evolution of potent dopamine D4 receptor ligands.
Bioorganic & medicinal chemistry letters, , May-07, Volume: 11, Issue:9, 2001

A perspective on natural products research and ethnopharmacology in Mexico: the eagle and the serpent on the prickly pear cactus.
Journal of natural products, , Mar-28, Volume: 77, Issue:3, 2014

Discovery of New Potent Positive Allosteric Modulators of Dopamine D
Journal of medicinal chemistry, , 05-13, Volume: 64, Issue:9, 2021

Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Journal of medicinal chemistry, , Feb-25, Volume: 42, Issue:4, 1999

QSAR prediction of D2 receptor antagonistic activity of 6-methoxy benzamides.
European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010

Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist
Journal of medicinal chemistry, , Jan-26, Volume: 49, Issue:2, 2006

Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 15, Issue:21, 2005

Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists.
Journal of medicinal chemistry, , Jul-22, Volume: 37, Issue:15, 1994

[no title available]
Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020

Remote functionalization of SCH 39166: discovery of potent and selective benzazepine dopamine D1 receptor antagonists.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010

Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 15, Issue:21, 2007

Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D
ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020

Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000

Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Bioorganic & medicinal chemistry, , 09-01, Volume: 25, Issue:17, 2017

Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

(1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide.
Journal of medicinal chemistry, , Dec-10, Volume: 36, Issue:25, 1993

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
Journal of medicinal chemistry, , Sep-11, Volume: 46, Issue:19, 2003

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
Journal of medicinal chemistry, , Apr-06, Volume: 43, Issue:7, 2000

Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993

Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agent.
Journal of medicinal chemistry, , Dec-22, Volume: 38, Issue:26, 1995

The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents.
Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994

Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Journal of medicinal chemistry, , Jul-14, Volume: 54, Issue:13, 2011

Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]pip eri dine.
Journal of medicinal chemistry, , May-23, Volume: 40, Issue:11, 1997

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996

Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000

Novel derivatives of 3-(dipropylamino)chroman. Interactions with 5-HT1A and D2A receptors.
Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 9, Issue:11, 1999

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016

Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.
Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004

Studies on quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides. 8.1, 2 synthesis and pharmacological evaluation of tricyclic fused quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides as potential alpha1-adrenoceptor antagonists.
Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998

[no title available]
Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
Journal of medicinal chemistry, , Jul-15, Volume: 42, Issue:14, 1999

4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor.
Journal of medicinal chemistry, , Jul-18, Volume: 40, Issue:15, 1997

5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors.
Journal of medicinal chemistry, , May-10, Volume: 39, Issue:10, 1996

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.
Journal of medicinal chemistry, , Apr-24, Volume: 57, Issue:8, 2014

Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.
Bioorganic & medicinal chemistry, , Jul-15, Volume: 18, Issue:14, 2010

Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 17, Issue:4, 2009

Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.
Journal of medicinal chemistry, , Oct-09, Volume: 51, Issue:19, 2008

Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 17, Issue:3, 2007

3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
Journal of medicinal chemistry, , May-10, Volume: 39, Issue:10, 1996

Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020

4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist.
Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985

[no title available]
,

(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991

Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application.
Journal of medicinal chemistry, , Volume: 27, Issue:6, 1984

Binding of beta-carbolines at 5-HT(2) serotonin receptors.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 13, Issue:24, 2003

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.
Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020

Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.
Journal of medicinal chemistry, , Dec-16, Volume: 47, Issue:26, 2004

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996

Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).
Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985

Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010

Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
Bioorganic & medicinal chemistry, , Jun-01, Volume: 17, Issue:11, 2009

Synthesis and dopaminergic activity of pyridine analogs of 5-hydroxy-2-(di-n-propylamino)tetralin.
Journal of medicinal chemistry, , Aug-04, Volume: 38, Issue:16, 1995

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
Journal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
Journal of medicinal chemistry, , Jan-22, Volume: 58, Issue:2, 2015

N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.
Journal of medicinal chemistry, , Nov-24, Volume: 38, Issue:24, 1995

Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 20, Issue:2, 2010

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
ACS medicinal chemistry letters, , Apr-10, Volume: 5, Issue:4, 2014

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 22, Issue:19, 2012

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 21, Issue:15, 2011

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A highly selective antagonist at cloned human D4 receptors.
Journal of medicinal chemistry, , Jan-03, Volume: 40, Issue:1, 1997

[no title available]
,

Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.
Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010

Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones.
Journal of enzyme inhibition and medicinal chemistry, , Volume: 29, Issue:2, 2014

Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014

Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 23, Issue:2, 2013

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010

Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Bioorganic & medicinal chemistry, , Mar-01, Volume: 18, Issue:5, 2010

New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.
Bioorganic & medicinal chemistry letters, , Sep-03, Volume: 11, Issue:17, 2001

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019

Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships.
Journal of medicinal chemistry, , Aug-02, Volume: 39, Issue:16, 1996

Binding of beta-carbolines at 5-HT(2) serotonin receptors.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 13, Issue:24, 2003

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.
Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.
Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 18, Issue:14, 2008

[no title available]
,

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 22, Issue:19, 2012

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 21, Issue:15, 2011

[no title available]
,

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009

Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: synthesis and dopamine receptor binding profiles.
Bioorganic & medicinal chemistry letters, , Sep-04, Volume: 10, Issue:17, 2000

Enantio- and diastereocontrolled dopamine D1, D2, D3 and D4 receptor binding of N-(3-pyrrolidinylmethyl)benzamides synthesized from aspartic acid.
Bioorganic & medicinal chemistry letters, , Mar-22, Volume: 9, Issue:6, 1999

Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).
Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985

[no title available]
,

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
Journal of medicinal chemistry, , Aug-09, Volume: 55, Issue:15, 2012

[no title available]
,

Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.
Bioorganic & medicinal chemistry, , Apr-15, Volume: 17, Issue:8, 2009

Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020

Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
Journal of medicinal chemistry, , 08-25, Volume: 59, Issue:16, 2016

Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding?
Journal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014

Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 15, Issue:21, 2007

Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019

Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018

Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010

Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
Journal of medicinal chemistry, , Volume: 32, Issue:9, 1989

Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021

Improving selectivity of dopamine D3 receptor ligands.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
Journal of medicinal chemistry, , May-26, Volume: 54, Issue:10, 2011

Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
Bioorganic & medicinal chemistry, , Dec-01, Volume: 15, Issue:23, 2007

Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Journal of medicinal chemistry, , Feb-08, Volume: 50, Issue:3, 2007

Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.
Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
Journal of medicinal chemistry, , Jun-02, Volume: 48, Issue:11, 2005

N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003

Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002

10-substituted 11-oxygenated (R)-aporphines: synthesis, pharmacology, and modeling of 5-HT1A receptor interactions.
Journal of medicinal chemistry, , Aug-30, Volume: 39, Issue:18, 1996

(R)-11-hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions.
Journal of medicinal chemistry, , Feb-17, Volume: 38, Issue:4, 1995

N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist.
Journal of medicinal chemistry, , Mar-17, Volume: 38, Issue:6, 1995

The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function b
Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998

Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002

A structure-affinity relationship study on derivatives of N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective D(4) receptor ligand.
Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000

N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
Journal of medicinal chemistry, , Nov-19, Volume: 41, Issue:24, 1998

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006

The role of QSAR in dopamine interactions.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 15, Issue:8, 2005

Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
Bioorganic & medicinal chemistry letters, , Jan-22, Volume: 11, Issue:2, 2001

Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.
Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997

Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 18, Issue:13, 2008

Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007

Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
Journal of medicinal chemistry, , Mar-23, Volume: 49, Issue:6, 2006

Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors.
Journal of medicinal chemistry, , Oct-19, Volume: 49, Issue:21, 2006

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
Journal of medicinal chemistry, , Jul-15, Volume: 47, Issue:15, 2004

Binding of beta-carbolines at 5-HT(2) serotonin receptors.
Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 13, Issue:24, 2003

[no title available]
Bioorganic & medicinal chemistry letters, , 06-01, Volume: 28, Issue:10, 2018

Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23, 2015

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010

Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
Bioorganic & medicinal chemistry letters, , Sep-02, Volume: 12, Issue:17, 2002

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.
Bioorganic & medicinal chemistry, , Apr-15, Volume: 17, Issue:8, 2009

4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 15, Issue:16, 2005

4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.
Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002

Solid-phase synthesis of 2,3-disubstituted indoles: discovery of a novel, high-affinity, selective h5-HT2A antagonist.
Bioorganic & medicinal chemistry letters, , Dec-18, Volume: 10, Issue:24, 2000

Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021

Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D
ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020

The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D
Journal of medicinal chemistry, , 07-11, Volume: 62, Issue:13, 2019

Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000

Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
Journal of medicinal chemistry, , Apr-26, Volume: 44, Issue:9, 2001

(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.
Journal of medicinal chemistry, , Feb-26, Volume: 41, Issue:5, 1998

Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 18, Issue:2, 2008

Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.
Bioorganic & medicinal chemistry letters, , May-20, Volume: 12, Issue:10, 2002

Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
Journal of medicinal chemistry, , Oct-15, Volume: 36, Issue:21, 1993

5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
Journal of medicinal chemistry, , Nov-22, Volume: 39, Issue:24, 1996

Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
Journal of medicinal chemistry, , Nov-25, Volume: 37, Issue:24, 1994

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995

Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.
European journal of medicinal chemistry, , Volume: 48, 2012

Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?
Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009

trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
Journal of medicinal chemistry, , Nov-16, Volume: 49, Issue:23, 2006

trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.
Bioorganic & medicinal chemistry letters, , May-17, Volume: 9, Issue:10, 1999

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995

Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
Journal of medicinal chemistry, , Jul-22, Volume: 37, Issue:15, 1994

Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
Journal of medicinal chemistry, , Apr-06, Volume: 43, Issue:7, 2000

Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity.
Journal of medicinal chemistry, , Apr-14, Volume: 38, Issue:8, 1995

Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration
Journal of medicinal chemistry, , Jan-10, Volume: 51, Issue:1, 2008

Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety.
Journal of medicinal chemistry, , Jul-04, Volume: 45, Issue:14, 2002

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996

3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
Journal of medicinal chemistry, , May-10, Volume: 39, Issue:10, 1996

Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
Journal of medicinal chemistry, , May-14, Volume: 36, Issue:10, 1993

Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
Journal of medicinal chemistry, , Apr-26, Volume: 44, Issue:9, 2001

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000

A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.
Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995

Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.
European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017

Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 22, Issue:21, 2014

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013

Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012

Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?
Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009

Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.
European journal of medicinal chemistry, , Volume: 53, 2012

Multi-target-directed ligands to combat neurodegenerative diseases.
Journal of medicinal chemistry, , Feb-14, Volume: 51, Issue:3, 2008

N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands.
Journal of medicinal chemistry, , Nov-08, Volume: 44, Issue:23, 2001

Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).
Bioorganic & medicinal chemistry letters, , Jan-08, Volume: 11, Issue:1, 2001

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014

Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.
Journal of medicinal chemistry, , 12-08, Volume: 59, Issue:23, 2016

Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994

[no title available]
Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
Journal of medicinal chemistry, , Jul-15, Volume: 47, Issue:15, 2004

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.
Bioorganic & medicinal chemistry letters, , Apr-07, Volume: 8, Issue:7, 1998

Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
Journal of medicinal chemistry, , Jun-02, Volume: 48, Issue:11, 2005

trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.
Bioorganic & medicinal chemistry letters, , May-17, Volume: 9, Issue:10, 1999

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000

Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists.
Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010

Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters, , Jul-19, Volume: 9, Issue:14, 1999

Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
Journal of medicinal chemistry, , Jun-28, Volume: 50, Issue:13, 2007

Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones.
Journal of enzyme inhibition and medicinal chemistry, , Volume: 29, Issue:2, 2014

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.
Bioorganic & medicinal chemistry, , Sep-15, Volume: 23, Issue:18, 2015

Bioisosteric replacement leading to biologically active [2.2]paracyclophanes with altered binding profiles for aminergic G-protein-coupled receptors.
Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010

Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Journal of medicinal chemistry, , Feb-08, Volume: 50, Issue:3, 2007

Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002

Identification of novel allosteric modulators for the G-protein coupled US28 receptor of human cytomegalovirus.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 21, Issue:18, 2011

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Journal of medicinal chemistry, , Jul-23, Volume: 58, Issue:14, 2015

Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.
Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
Journal of medicinal chemistry, , May-26, Volume: 54, Issue:10, 2011

Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
Journal of medicinal chemistry, , Jun-02, Volume: 48, Issue:11, 2005

NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.
Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998

Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993

Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 17, Issue:4, 2009

Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008

Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.
Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 16, Issue:12, 2006

Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.
Journal of medicinal chemistry, , Jan-29, Volume: 47, Issue:3, 2004

[11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors.
Bioorganic & medicinal chemistry, , Jul-01, Volume: 16, Issue:13, 2008

Research progress in biological activities of isochroman derivatives.
European journal of medicinal chemistry, , Jan-15, Volume: 210, 2021

Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-(( trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity
Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019

[no title available]
Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017

Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
Journal of medicinal chemistry, , Jul-09, Volume: 58, Issue:13, 2015

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010

Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity.
Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011

Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding?
Journal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014

A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride.
Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 15, Issue:21, 2007

Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen.
Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 18, Issue:20, 2008

Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties.
Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 18, Issue:20, 2008

Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
Journal of medicinal chemistry, , Aug-23, Volume: 55, Issue:16, 2012

[no title available]
Journal of medicinal chemistry, , 09-22, Volume: 65, Issue:18, 2022

1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D
Journal of medicinal chemistry, , 04-26, Volume: 61, Issue:8, 2018

3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 17, Issue:4, 2007

Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.
Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008

11-substituted (R)-aporphines: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions.
Journal of medicinal chemistry, , Aug-30, Volume: 39, Issue:18, 1996

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Discovery of highly potent and selective D4 ligands by interactive SAR study.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 23, Issue:18, 2013

Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Discovery of a dopamine D4 selective PET ligand candidate taking advantage of a click chemistry based REM linker.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: discovery of an inverse agonist radioligand for PET.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Journal of medicinal chemistry, , Feb-08, Volume: 50, Issue:3, 2007

Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
Journal of medicinal chemistry, , Apr-22, Volume: 47, Issue:9, 2004

Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213).
Journal of medicinal chemistry, , Aug-16, Volume: 44, Issue:17, 2001

Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.
Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009

Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008

Return of D
Journal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017

Identification of a new selective dopamine D4 receptor ligand.
Bioorganic & medicinal chemistry, , Jun-15, Volume: 22, Issue:12, 2014

Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: discovery of an inverse agonist radioligand for PET.
Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008

Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Journal of medicinal chemistry, , Feb-08, Volume: 50, Issue:3, 2007

2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
Journal of medicinal chemistry, , Jun-29, Volume: 49, Issue:13, 2006

Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356.
Bioorganic & medicinal chemistry letters, , Aug-05, Volume: 12, Issue:15, 2002

Di- and trisubstituted pyrazolo[1,5-a]pyridine derivatives: synthesis, dopamine receptor binding and ligand efficacy.
Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002

Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213).
Journal of medicinal chemistry, , Aug-16, Volume: 44, Issue:17, 2001

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 15, Issue:21, 2007

Dopamine D
Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019

Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998

A new class of selective, non-basic 5-HT2A receptor antagonists.
Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 16, Issue:12, 2006

4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 15, Issue:16, 2005

4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.
Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002

Novel D
European journal of medicinal chemistry, , Mar-15, Volume: 232, 2022

[no title available]
Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021

2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021

[no title available]
Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019

Synthetic Approaches to the New Drugs Approved During 2015.
Journal of medicinal chemistry, , 08-10, Volume: 60, Issue:15, 2017

Development of molecular tools based on the dopamine D
Bioorganic & medicinal chemistry, , 07-01, Volume: 25, Issue:13, 2017

Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
European journal of medicinal chemistry, , Nov-10, Volume: 123, 2016

Functionally selective dopamine D₂, D₃ receptor partial agonists.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

A structure-activity analysis of biased agonism at the dopamine D2 receptor.
Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.
Journal of medicinal chemistry, , Feb-23, Volume: 49, Issue:4, 2006

[no title available]
Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022

Imidazopyridine-Based 5-HT
Journal of medicinal chemistry, , 01-28, Volume: 64, Issue:2, 2021

Novel non-sulfonamide 5-HT
European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016

Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.
ACS medicinal chemistry letters, , Oct-26, Volume: 3, Issue:12, 2012

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Journal of medicinal chemistry, , Jul-23, Volume: 58, Issue:14, 2015

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
Journal of medicinal chemistry, , May-26, Volume: 54, Issue:10, 2011

Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007

Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Journal of medicinal chemistry, , Feb-10, Volume: 48, Issue:3, 2005

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
Journal of medicinal chemistry, , Jun-02, Volume: 48, Issue:11, 2005

Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
Journal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007

Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?
Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009

Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 18, Issue:13, 2008

Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007

Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
Journal of medicinal chemistry, , Mar-23, Volume: 49, Issue:6, 2006

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Journal of medicinal chemistry, , Jul-23, Volume: 58, Issue:14, 2015

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.
Bioorganic & medicinal chemistry, , Nov-01, Volume: 20, Issue:21, 2012

[no title available]
Journal of medicinal chemistry, , 11-14, Volume: 62, Issue:21, 2019

2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 207, 2020

Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
Bioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019

Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.
Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Proceedings of the National Academy of Sciences of the United States of America, , May-15, Volume: 104, Issue:20, 2007

Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.
Journal of medicinal chemistry, , Jul-12, Volume: 50, Issue:14, 2007

[no title available]
European journal of medicinal chemistry, , Jan-01, Volume: 185, 2020

Search for a 5-CT alternative.
MedChemComm, , Nov-01, Volume: 9, Issue:11, 2018

Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case study.
European journal of medicinal chemistry, , Sep-14, Volume: 120, 2016

Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008

Spiroindolones, a potent compound class for the treatment of malaria.
Science (New York, N.Y.), , Sep-03, Volume: 329, Issue:5996, 2010

[no title available]
,

Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.
Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 21, Issue:21, 2011

Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Journal of medicinal chemistry, , Oct-22, Volume: 58, Issue:20, 2015

Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors.
Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021

Target	Category	Definition
dopamine neurotransmitter receptor activity, coupled via Gi/Go	molecular function	Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gi/Go to initiate a change in cell activity. [GOC:mah, ISBN:0953351033, IUPHAR_RECEPTOR:2254, IUPHAR_RECEPTOR:2256, IUPHAR_RECEPTOR:2258]
G-protein alpha-subunit binding	molecular function	Binding to a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide. [GOC:hjd]
protein binding	molecular function	Binding to a protein. [GOC:go_curators]
heterotrimeric G-protein binding	molecular function	Binding to a heterotrimeric G-protein. [GOC:nln]
dopamine binding	molecular function	Binding to dopamine, a catecholamine neurotransmitter formed by aromatic-L-amino-acid decarboxylase from 3,4-dihydroxy-L-phenylalanine. [ISBN:0198506732]
ionotropic glutamate receptor binding	molecular function	Binding to an ionotropic glutamate receptor. Ionotropic glutamate receptors bind glutamate and exert an effect through the regulation of ion channels. [GOC:bf, ISBN:0198506732]
identical protein binding	molecular function	Binding to an identical protein or proteins. [GOC:jl]
heterocyclic compound binding	molecular function	Binding to heterocyclic compound. [GOC:TermGenie]
G protein-coupled receptor activity	molecular function	Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. [GOC:bf, http://www.iuphar-db.org, Wikipedia:GPCR]

Target	Category	Definition
Golgi membrane	cellular component	The lipid bilayer surrounding any of the compartments of the Golgi apparatus. [GOC:mah]
acrosomal vesicle	cellular component	A structure in the head of a spermatozoon that contains acid hydrolases, and is concerned with the breakdown of the outer membrane of the ovum during fertilization. It lies just beneath the plasma membrane and is derived from the lysosome. [ISBN:0124325653, ISBN:0198506732]
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]
cilium	cellular component	A specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface and of some cytoplasmic parts. Each cilium is largely bounded by an extrusion of the cytoplasmic (plasma) membrane, and contains a regular longitudinal array of microtubules, anchored to a basal body. [GOC:cilia, GOC:curators, GOC:kmv, GOC:vw, ISBN:0198547684, PMID:16824949, PMID:17009929, PMID:20144998]
lateral plasma membrane	cellular component	The portion of the plasma membrane at the lateral side of the cell. In epithelial cells, lateral plasma membranes are on the sides of cells which lie at the interface of adjacent cells. [GOC:hb, GOC:mah, GOC:pr]
endocytic vesicle	cellular component	A membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance. Endocytic vesicles fuse with early endosomes to deliver the cargo for further sorting. [GOC:go_curators, PMID:19696797]
axon	cellular component	The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter. [GOC:nln, ISBN:0198506732]
dendrite	cellular component	A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732]
synaptic vesicle membrane	cellular component	The lipid bilayer surrounding a synaptic vesicle. [GOC:mah]
sperm flagellum	cellular component	A microtubule-based flagellum (or cilium) that is part of a sperm, a mature male germ cell that develops from a spermatid. [GOC:cilia, GOC:sart, PMID:8441407]
dendritic spine	cellular component	A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln]
perikaryon	cellular component	The portion of the cell soma (neuronal cell body) that excludes the nucleus. [GOC:jl]
axon terminus	cellular component	Terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters. The axon terminus is considered to be the whole region of thickening and the terminal button is a specialized region of it. [GOC:dph, GOC:jl]
postsynaptic membrane	cellular component	A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732]
ciliary membrane	cellular component	The portion of the plasma membrane surrounding a cilium. [GOC:cilia, GOC:dph, GOC:rph]
non-motile cilium	cellular component	A cilium which may have a variable array of axonemal microtubules but does not contain molecular motors. [GOC:cilia, GOC:dgh, GOC:kmv, PMID:17009929, PMID:20144998, PMID:22118931]
dopaminergic synapse	cellular component	A synapse that uses dopamine as a neurotransmitter. [GOC:dos]
GABA-ergic synapse	cellular component	A synapse that uses GABA as a neurotransmitter. These synapses are typically inhibitory. [GOC:dos]

Target	Category	Definition
glutamatergic synapse	cellular component	A synapse that uses glutamate as a neurotransmitter. [GOC:dos]
presynaptic membrane	cellular component	A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane. [GOC:jl, ISBN:0815316194]
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]

Target	Category	Definition
temperature homeostasis	biological process	A homeostatic process in which an organism modulates its internal body temperature. [GOC:jl]
response to hypoxia	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. [GOC:hjd]
negative regulation of protein phosphorylation	biological process	Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein. [GOC:hjd]
response to amphetamine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine. [GOC:dph, GOC:ef]
nervous system process involved in regulation of systemic arterial blood pressure	biological process	The regulation of blood pressure mediated by detection of stimuli and a neurological response. [GOC:mtg_cardio, ISBN:0721643949]
regulation of heart rate	biological process	Any process that modulates the frequency or rate of heart contraction. [GOC:dph, GOC:tb, PMID:10358008]
regulation of sodium ion transport	biological process	Any process that modulates the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:dph]
G protein-coupled receptor internalization	biological process	The process that results in the uptake of a G protein-coupled receptor into an endocytic vesicle. [PMID:8396717]
positive regulation of neuroblast proliferation	biological process	Any process that activates or increases the rate of neuroblast proliferation. [GOC:dph]
positive regulation of receptor internalization	biological process	Any process that activates or increases the frequency, rate or extent of receptor internalization. [GOC:hjd]
autophagy	biological process	The cellular catabolic process in which cells digest cellular materials, such as organelles and other macromolecular constituents, or non-self materials such as intracellular pathogens. Autophagy serves to provide essential nutrients under conditions of cellular stress; or can remodel intracellular structures during cell differentiation. [GOC:autophagy, ISBN:0198547684, PMID:11099404, PMID:29455577, PMID:9412464]
adenylate cyclase-inhibiting dopamine receptor signaling pathway	biological process	An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor, and ending with the regulation of a downstream cellular process. [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]
neuron-neuron synaptic transmission	biological process	The process of synaptic transmission from a neuron to another neuron across a synapse. [GOC:add, GOC:dos, GOC:jl, MeSH:D009435]
neuroblast proliferation	biological process	The expansion of a neuroblast population by cell division. A neuroblast is any cell that will divide and give rise to a neuron. [GOC:ai, GOC:mtg_sensu, GOC:sart]
axonogenesis	biological process	De novo generation of a long process of a neuron, including the terminal branched region. Refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent (outgoing) action potentials from the cell body towards target cells. [GOC:dph, GOC:jid, GOC:pg, GOC:pr, ISBN:0198506732]
synapse assembly	biological process	The aggregation, arrangement and bonding together of a set of components to form a synapse. This process ends when the synapse is mature (functional). [GOC:mah]
sensory perception of smell	biological process	The series of events required for an organism to receive an olfactory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Olfaction involves the detection of chemical composition of an organism's ambient medium by chemoreceptors. This is a neurological process. [GOC:ai]
long-term memory	biological process	The memory process that deals with the storage, retrieval and modification of information a long time (typically weeks, months or years) after receiving that information. This type of memory is typically dependent on gene transcription regulated by second messenger activation. [http://hebb.mit.edu/courses/9.03/lecture4.html, ISBN:0582227089]
grooming behavior	biological process	The specific behavior of an organism relating to grooming, cleaning and brushing to remove dirt and parasites. [GOC:jl, GOC:pr]
locomotory behavior	biological process	The specific movement from place to place of an organism in response to external or internal stimuli. Locomotion of a whole organism in a manner dependent upon some combination of that organism's internal state and external conditions. [GOC:dph]
adult walking behavior	biological process	The behavior of an adult relating to the progression of that organism along the ground by the process of lifting and setting down each leg. [GOC:jid, GOC:pr, ISBN:0198606907]
protein localization	biological process	Any process in which a protein is transported to, or maintained in, a specific location. [GOC:ai]
negative regulation of cell population proliferation	biological process	Any process that stops, prevents or reduces the rate or extent of cell proliferation. [GOC:go_curators]
associative learning	biological process	Learning by associating a stimulus (the cause) with a particular outcome (the effect). [ISBN:0582227089]
visual learning	biological process	Any process in an organism in which a change in behavior of an individual occurs in response to repeated exposure to a visual cue. [GOC:jid, ISBN:0582227089]
response to xenobiotic stimulus	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc]
response to light stimulus	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light stimulus, electromagnetic radiation of wavelengths classified as infrared, visible or ultraviolet light. [GOC:go_curators, ISBN:0582227089]
response to toxic substance	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus. [GOC:lr]
response to iron ion	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus. [GOC:sm]
response to inactivity	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inactivity stimulus. [GOC:mtg_muscle]
Wnt signaling pathway	biological process	The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of a target cell and ending with a change in cell state. [PMID:11532397]
striatum development	biological process	The progression of the striatum over time from its initial formation until its mature state. The striatum is a region of the forebrain consisting of the caudate nucleus, putamen and fundus striati. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]
orbitofrontal cortex development	biological process	The progression of the orbitofrontal cortex over time from its initial formation until its mature state. The orbitofrontal cortex is a cerebral cortex region located in the frontal lobe. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]
cerebral cortex GABAergic interneuron migration	biological process	The migration of GABAergic interneuron precursors from the subpallium to the cerebral cortex. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]
adenohypophysis development	biological process	The progression of the adenohypophysis over time from its initial formation until its mature state. The adenohypophysis is the anterior part of the pituitary. It secretes a variety of hormones and its function is regulated by the hypothalamus. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]
negative regulation of cell migration	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of cell migration. [GOC:go_curators]
peristalsis	biological process	A wavelike sequence of involuntary muscular contraction and relaxation that passes along a tubelike structure, such as the intestine, impelling the contents onwards. [ISBN:0198506732]
auditory behavior	biological process	The behavior of an organism in response to a sound. [GOC:pr, GOC:rc]
regulation of synaptic transmission, GABAergic	biological process	Any process that modulates the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA). [GOC:mah]
positive regulation of cytokinesis	biological process	Any process that activates or increases the frequency, rate or extent of the division of the cytoplasm of a cell, and its separation into two daughter cells. [GOC:mah]
circadian regulation of gene expression	biological process	Any process that modulates the frequency, rate or extent of gene expression such that an expression pattern recurs with a regularity of approximately 24 hours. [GOC:mah]
negative regulation of dopamine secretion	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine. [GOC:sl]
response to histamine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histamine stimulus. Histamine, the biogenic amine 2-(1H-imidazol-4-yl)ethanamine, is involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter. [GOC:BHF, GOC:mah, GOC:vk]
response to nicotine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus. [GOC:bf, GOC:ef, ISBN:0198506732, ISBN:0582227089]
positive regulation of urine volume	biological process	Any process that increases the amount of urine excreted from the body over a unit of time. [GOC:mtg_25march11, GOC:yaf]
positive regulation of renal sodium excretion	biological process	Any process that increases the amount of sodium excreted in urine over a unit of time. [GOC:mtg_25march11, GOC:yaf]
positive regulation of multicellular organism growth	biological process	Any process that activates or increases the frequency, rate or extent of growth of an organism to reach its usual body size. [GOC:dph, GOC:go_curators, GOC:tb]
response to cocaine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant. [GOC:ef, GOC:jl]
negative regulation of circadian sleep/wake cycle, sleep	biological process	Any process that stops, prevents or reduces the duration or quality of sleep, a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals. [GOC:go_curators, GOC:jl, ISBN:0192800981]
dopamine metabolic process	biological process	The chemical reactions and pathways involving dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. [GOC:jl, ISBN:0198506732]
drinking behavior	biological process	The specific behavior of an organism relating to the intake of liquids, especially water. [GOC:curators, GOC:pr]
regulation of potassium ion transport	biological process	Any process that modulates the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:jl]
response to morphine	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure. [GOC:ef, GOC:jl]
pigmentation	biological process	The accumulation of pigment in an organism, tissue or cell, either by increased deposition or by increased number of cells. [GOC:jl]
phosphatidylinositol 3-kinase/protein kinase B signal transduction	biological process	An intracellular signaling cassette that starts with phosphatidylinositol 3-kinase (PI3K) activation, production of phosphatidylinositol 3-phosphate (PI3P), activation of PDK1, which recruits and ending with the activation of protein kinase B (PKB, also known as Akt). PI3K is activated by cell surface receptors. Note that PTEN is an inhibitor of the pathway. [PMID:20517722, PMID:22952397]
positive regulation of G protein-coupled receptor signaling pathway	biological process	Any process that activates or increases the frequency, rate or extent of G protein-coupled receptor signaling pathway activity. [GOC:go_curators]
negative regulation of blood pressure	biological process	Any process in which the force of blood traveling through the circulatory system is decreased. [GOC:go_curators, GOC:mtg_cardio]
negative regulation of innate immune response	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response. [GOC:go_curators]
positive regulation of transcription by RNA polymerase II	biological process	Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. [GOC:go_curators, GOC:txnOH]
negative regulation of insulin secretion	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin. [GOC:ai]
acid secretion	biological process	The controlled release of acid by a cell or a tissue. [GOC:ai]
behavioral response to cocaine	biological process	Any process that results in a change in the behavior of an organism as a result of a cocaine stimulus. [GOC:jid]
behavioral response to ethanol	biological process	Any process that results in a change in the behavior of an organism as a result of an ethanol stimulus. [GOC:jid]
regulation of long-term neuronal synaptic plasticity	biological process	A process that modulates long-term neuronal synaptic plasticity, the ability of neuronal synapses to change long-term as circumstances require. Long-term neuronal synaptic plasticity generally involves increase or decrease in actual synapse numbers. [GOC:jid, PMID:11891290]
response to axon injury	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an axon injury stimulus. [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]
branching morphogenesis of a nerve	biological process	The process in which the anatomical structures of branches in a nerve are generated and organized. This term refers to an anatomical structure (nerve) not a cell (neuron). [GOC:dgh, GOC:dph, GOC:jid]
arachidonic acid secretion	biological process	The controlled release of arachidonic acid from a cell or a tissue. [GOC:ai]
epithelial cell proliferation	biological process	The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population. Epithelial cells make up the epithelium, the covering of internal and external surfaces of the body, including the lining of vessels and other small cavities. It consists of cells joined by small amounts of cementing substances. [ISBN:0721662544]
negative regulation of epithelial cell proliferation	biological process	Any process that stops, prevents or reduces the rate or extent of epithelial cell proliferation. [GOC:ai]
negative regulation of protein secretion	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a protein from a cell. [GOC:ai]
release of sequestered calcium ion into cytosol	biological process	The process in which calcium ions sequestered in the endoplasmic reticulum, Golgi apparatus or mitochondria are released into the cytosolic compartment. [GOC:dph, GOC:hjd, GOC:mtg_lung, PMID:1814929]
dopamine uptake involved in synaptic transmission	biological process	The directed movement of dopamine into a presynaptic neuron or glial cell. In this context, dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. [GOC:ai]
regulation of dopamine uptake involved in synaptic transmission	biological process	Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell. [GOC:ai]
positive regulation of dopamine uptake involved in synaptic transmission	biological process	Any process that activates or increases the frequency, rate or extent of the directed movement of dopamine into a cell. [GOC:ai]
regulation of synapse structural plasticity	biological process	Any process that modulates the frequency, rate or extent of synapse structural plasticity. Synapse structural plasticity is a type of cytoskeletal remodeling; this remodeling is induced by stimuli that can lead to long term potentiation and it can be activity-dependent or -independent. Examples of cytoskeletal changes include the formation of new spines and increase in spine size; this can be accompanied by the insertion of greater numbers of glutamate (or other neurotransmitter) receptors into the post-synaptic membrane. [PMID:11063967, PMID:14976517, PMID:9884123]
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction. [GOC:ai]
negative regulation of synaptic transmission, glutamatergic	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. [GOC:ai]
excitatory postsynaptic potential	biological process	A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:dph, GOC:ef]
positive regulation of growth hormone secretion	biological process	Any process that increases the frequency, rate or extent of the regulated release of growth hormone from a cell. [GOC:dph]
prepulse inhibition	biological process	The process in which a startle magnitude is reduced when the startling stimulus is preceded by a low-intensity prepulse. [GOC:dph, PMID:10341260]
negative regulation of dopamine receptor signaling pathway	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of dopamine receptor protein signaling pathway activity. A dopamine receptor signaling pathway is the series of molecular signals generated as a consequence of a dopamine receptor binding to one of its physiological ligands. [GOC:dph]
positive regulation of ERK1 and ERK2 cascade	biological process	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. [GOC:mah]
regulation of locomotion involved in locomotory behavior	biological process	Any process that modulates the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement. [GOC:dph, GOC:kmv, GOC:tb]
postsynaptic modulation of chemical synaptic transmission	biological process	Any process, acting in the postsynapse that results in modulation of chemical synaptic transmission. [GOC:dos]
presynaptic modulation of chemical synaptic transmission	biological process	Any process, acting in the presynapse that results in modulation of chemical synaptic transmission. [GOC:dos]
negative regulation of cellular response to hypoxia	biological process	Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to hypoxia. [GOC:TermGenie, GOC:yaf]
positive regulation of glial cell-derived neurotrophic factor production	biological process	Any process that activates or increases the frequency, rate or extent of glial cell-derived neurotrophic factor production. [GOC:TermGenie, GOC:yaf]
positive regulation of long-term synaptic potentiation	biological process	Any process that activates or increases the frequency, rate or extent of long-term synaptic potentiation. [GOC:BHF, GOC:TermGenie]
hyaloid vascular plexus regression	biological process	The developmental process in which the hyaloid vascular plexus is destroyed as a part of its normal progression. [GOC:hjd, PMID:18841878]
negative regulation of neuron migration	biological process	Any process that stops, prevents or reduces the frequency, rate or extent of neuron migration. [GOC:obol]
negative regulation of cytosolic calcium ion concentration	biological process	Any process that decreases the concentration of calcium ions in the cytosol. [GOC:ai]
regulation of dopamine secretion	biological process	Any process that modulates the frequency, rate or extent of the regulated release of dopamine. [GOC:ef]
negative regulation of adenylate cyclase activity	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity. [GOC:go_curators]
phospholipase C-activating dopamine receptor signaling pathway	biological process	A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:dph, GOC:signaling, GOC:tb, PMID:12675914]
negative regulation of voltage-gated calcium channel activity	biological process	Any process that stops, prevents or reduces the frequency, rate or extent of voltage-gated calcium channel activity. [GOC:BHF, GOC:TermGenie]
positive regulation of MAPK cascade	biological process	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. [GOC:go_curators]
adenylate cyclase-activating adrenergic receptor signaling pathway	biological process	An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process. [GOC:BHF, GOC:mah, GOC:signaling]

Synonyms

Research

Bioassay Publications (442)

Compounds (300)

Drugs with Inhibition Measurements

Drugs with Activation Measurements

Drugs with Other Measurements

Enables

Located In

Active In

Part Of

Involved In